Project Grant K99AG088296

Award Date 9/1/24
Completion Date 8/31/26
Dollars Obligated $224K
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Charlestown, MA 02129, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,001,864 to Harvard University to investigate the subcellular mechanisms underlying the selective vulnerability of specific neuron subtypes in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will quantitatively study the localization of RNA, proteins, and translational regulation in the synapses and soma of vulnerable corticospinal neurons (CSN) and...
This $208,750 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund a research project titled "Characterizing Autonomic Impairments in Frontotemporal Dementia" at The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The primary objectives are to: Assess the test-retest reliability of "gold-standard" measurements of autonomic function in 30 patients with behavioral variant frontotemporal...
This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $104,164 to Emory University to investigate the interaction between the TMEM106B gene and the C9ORF72 gene, which are both linked to frontotemporal dementia (FTD) and other neurodegenerative disorders. The research aims to determine how the TMEM106B protein interacts with the dipeptide repeat proteins produced by the C9ORF72 gene mutation, and to examine the toxicity of...
This $1,157,896 Project Grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), will fund research at Brown University focused on elucidating the mechanistic basis of transketolase-mediated suppression of neurodegeneration in amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD). The grantee will study multiple models of ALS/FTD using Drosophila genetics and analyze molecular readouts such as redox state, autophagy,...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $432,802 to Pennsylvania State University, doing business as Penn State Milton S. Hershey Medical Center, for a research project titled "Cross Validation of Gene Expression Changes in C9ORF72 FTD Using Drosophila and Human Model Systems." The project aims to identify and...
This $305,000 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) will support research at the University of Florida to investigate the effects of GRN gene mutations on motor and language deficits associated with frontotemporal dementia (FTD). The key objectives are to: Examine motor and non-motor behavioral deficits in a mouse model with striatum-specific GRN knockout. Analyze changes in striatal neuron properties, cholinergic interneurons, and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $452,550 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the role of reactive astrogliosis, specifically the upregulation of the glial fibrillary acidic protein (GFAP) in astrocytes, on synaptic dysfunction and loss in Alzheimer's disease. The researchers will examine how GFAP upregulation in reactive astrocytes impacts the protein...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $630,496 to the J. David Gladstone Institutes in San Francisco, CA to conduct research on the proteostasis, neuroinflammation, and neurodegeneration mechanisms involved in frontotemporal dementia (FTD) caused by GRN haploinsufficiency. The key objectives are to better define the alterations in proteostasis, autophagy/lysosomal function, and TDP-43 turnover in FTD neurons, microglia, and...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to develop a novel cellular model for investigating amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will directly convert patient-derived fibroblasts into neurons, preserving the epigenetic age of the starting cells, in order to...
This $460,625 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will support research to investigate the roles of the deubiquitylation pathway in TDP-43 pathology related to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The award, provided to the University of Massachusetts Medical School, will utilize mouse models and...

This $224,140 Project Grant was awarded by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for a project titled "Understanding the Relationship Between Cortical Hyperexcitability and the Progression of FTD/ALS Pathology and Behavioral Deficits in Mice".

The grant aims to elucidate the mechanisms of circuit dysfunction in frontotemporal dementia (FTD) caused by the C9ORF72 gene, focusing on understanding the relationship between cortical hyperactivity, the progression of C9ORF72 hexanucleotide repeat pathology, and behavioral deficits. The project will leverage state-of-the-art technologies such as multiphoton microscopy, optogenetics, and chemogenetics to monitor neuronal activity, evaluate its relationship to neuronal loss, and determine whether hyperactivity can drive the progression of FTD pathology and behavioral deficits. The goal is to develop effective and timely treatments for FTD. The award period is from September 1, 2024 to August 31, 2026.

Generated 7/1/25, 2:43 AM